MedTech Terms
    The authoritative reference
    All terms

    Pivotal Trial

    Definitive clinical study designed to establish safety and effectiveness for marketing authorization.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    A pivotal trial is the primary evidence base for a PMA, De Novo, or PMA Supplement, and increasingly for high-risk MDR submissions. Endpoints are pre-specified, statistical analysis plans are locked, and the study is typically powered for the regulatory hypothesis.
    What the regulation says
    Under FDA regulations, a pivotal trial provides the definitive clinical evidence required for premarket approval (PMA) of Class III devices, as outlined in 21 CFR Part 814. These trials are designed to demonstrate the safety and effectiveness of a device for its intended use. For CE marking under the EU MDR, similar rigorous clinical evidence, often from pivotal studies, is necessary for high-risk devices, as specified in Annex I, Chapter II, Section 6.

    What this means in practice

    Often preceded by feasibility and EFS studies and followed by post-approval/PMCF studies.

    Examples

    • A medical device manufacturer conducts a randomized controlled pivotal trial to compare the effectiveness of a novel cardiac stent against an already approved device for reducing restenosis rates.
    • For a new diagnostic imaging system, a pivotal trial enrolls a large cohort of patients to demonstrate its accuracy and reliability in detecting a specific medical condition compared to current diagnostic standards.
    • A company developing an implantable neurostimulation device performs a pivotal study to show its long-term safety and efficacy in managing chronic pain, with pre-specified outcome measures related to pain reduction and quality of life.
    Common pitfalls
    • •A common pitfall is conducting a pivotal trial without first establishing a clear statistical analysis plan, which can lead to questions about data integrity and interpretation.
    • •Failing to adequately power a pivotal trial for its primary endpoints can result in inconclusive results, necessitating additional studies.
    • •Misinterpreting preliminary data from feasibility or early feasibility studies as sufficient for regulatory submission is a frequent mistake.
    • •Not addressing potential biases in patient selection or data collection during the trial design phase can undermine the validity of the results.
    • •Neglecting to consider the long-term follow-up requirements for certain devices can lead to incomplete data at the time of submission.

    Frequently asked questions

    A pivotal trial is typically a large, well-controlled study intended to provide definitive evidence of a device's safety and effectiveness for regulatory approval, unlike earlier-phase studies that explore feasibility or gather preliminary data.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·2ISO·1
    1. 1
      FDA IDE Guidance
      Verified
      FDAfda.gov
    2. 2
      ISO 14155 Standard Page
      Verified
      ISOiso.org
    3. 3
      FDA - Clinical Trials and Human Subject Protection
      Verified
      FDAfda.gov

    Inline markers like [1] jump to the matching reference above.